Rhineland-Palatinate, speaks at the official ground-breaking ceremony for the construction of a new research and development ...
The third quarter of 2024 brought a mix of gains and modest declines for the pharmaceutical industry’s top players ...
Bristol-Myers Squibb Co (NYSE:BMY) shares are trading higher Monday. The stock appears to be reacting positively after AbbVie ...
Concluded targeted enrollment of Phase 3 INDIGO trial evaluating obexelimab for the treatment of Immunoglobulin G4-Related ...
Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two ...
The S&P 500 added 0.1% on Monday, Nov. 11, 2024, closing above the 6,000-point milestone as investors continued to weigh the ...
December S&P 500 E-Mini futures (ESZ24) are down -0.09%, and December Nasdaq 100 E-Mini futures (NQZ24) are down -0.14% this morning as investors assessed the potential policy impact of Donald Trump’s ...
Meanwhile, pharmaceutical company Bristol Myers Squibb surged 10.49 percent on Monday, its biggest single-day rise since March 2020. This increase followed news that AbbVie's top schizophrenia drug ...
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course ...
AbbVie reports disappointing mid-stage data for its schizophrenia drug. Jason Snipe of Odyssey Capital still likes AbbVie ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback